<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
11.02.2020 16:33:00

Is Gilead Sciences an Acquisition Target?

Gilead Sciences' (NASDAQ: GILD) latest earnings report and full-year outlook didn't exactly inspire confidence among investors last week. The biotech heavyweight told the investing community a week ago today that its top line will likely dip yet again this year thanks to falling hep C drug sales and the slower-than-expected commercialization of its anti-cancer cell therapy Yescarta.Wall Street, for its part, is even less optimistic about the big biotech's near-term prospects. The average analyst estimate has the biotech's annual sales declining for the next two full years. That's a surprising take to be sure, given the strong possibility that Gilead's blockbuster-in-waiting, filgotinib, will likely hit the market soon.  The big deal is that the biotech's market capitalization has been bumping up against its five-year low lately thanks to this rather anemic outlook. In response, Jefferies' analyst Michael Yee published a note last week suggesting that Gilead might now be an attractive takeover target. Its large-cap biopharma peers Allergan and Celgene, after all, both turned into top acquisition targets when their respective market caps bottomed out. Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Analysen zu Gilead Sciences Inc.mehr Analysen

15.03.19 Gilead Sciences Outperform BMO Capital Markets
03.01.19 Gilead Sciences Outperform Oppenheimer & Co. Inc.
26.10.18 Gilead Sciences overweight Barclays Capital
01.10.18 Gilead Sciences Overweight Cantor Fitzgerald
26.07.18 Gilead Sciences Neutral Robert W. Baird & Co. Incorporated

Eintrag hinzufügen

Aktien Top Flop

Alcon 48.74
8.06 %
Roche Hldg G 308.80
4.10 %
Swisscom 536.00
4.08 %
Givaudan 2'975.00
3.84 %
Lonza Grp 393.80
3.14 %
Adecco Group 36.78
-0.51 %
Swiss Re 70.30
-0.54 %
CS Group 8.00
-0.67 %
CieFinRichemont 52.10
-1.51 %
ABB 16.64
-5.78 %
Noch keine Entwarnung nach starken Gewinnen | BX Swiss TV

Aktien in diesem Artikel

Gilead Sciences Inc. 66.00 3.77% Gilead Sciences Inc.

Finanzen.net News

pagehit